Ocugen, Inc (OCGN)

NASDAQ
Currency in USD
0.712
-0.012(-1.38%)
Closed
Pre Market
0.726+0.014(+1.97%)
OCGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.7080.743
52 wk Range
0.5502.105
Key Statistics
Edit
Prev. Close
0.725
Open
0.722
Day's Range
0.708-0.743
52 wk Range
0.55-2.105
Volume
3.64M
Average Volume (3m)
4.71M
1-Year Change
32.34%
Book Value / Share
0.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OCGN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.250
Upside
+777.81%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Ocugen Company Profile

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Ocugen, Inc Earnings Call Summary for Q3/2024

  • Ocugen advances Phase III trial for retinitis pigmentosa, expanding into Canada; no serious adverse events reported
  • Q3 2024: $39M cash, $14.4M operating expenses; $30M debt financing extends runway to Q1 2026
  • Stock closed at $0.876 (-2.22%), rebounded to $0.881 (+0.55%) in aftermarket trading
  • OcQ400 Phase III enrollment completion targeted for H1 2025; regulatory filings planned for 2026
  • CEO emphasizes safety and efficacy of gene therapy products; ORQ200 Phase 1 trial to begin Q4 2024
Last Updated: 08-01-2025, 01:54 pm
Read Full Transcript

Compare OCGN to Peers and Sector

Metrics to compare
OCGN
Peers
Sector
Relationship
P/E Ratio
−4.1x−2.4x−0.6x
PEG Ratio
−0.10−0.110.00
Price/Book
5.1x1.0x2.6x
Price / LTM Sales
44.2x12.6x3.1x
Upside (Analyst Target)
-171.1%47.1%
Fair Value Upside
Unlock31.2%8.1%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.250
(+777.81% Upside)

Earnings

Latest Release
Nov 08, 2024
EPS / Forecast
-0.055 / -0.06
Revenue / Forecast
1.14M / 400.00K
EPS Revisions
Last 90 days

FAQ

What Is the Ocugen (OCGN) Stock Price Today?

The Ocugen stock price today is 0.712.

What Stock Exchange Does Ocugen Trade On?

Ocugen is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Ocugen?

The stock symbol for Ocugen is "OCGN."

What Is the Ocugen Market Cap?

As of today, Ocugen market cap is 207.94M.

What is Ocugen Earnings Per Share?

The Ocugen EPS is -0.195.

What Is the Next Ocugen Earnings Date?

Ocugen will release its next earnings report on 27 Mar 2025.

From a Technical Analysis Perspective, Is OCGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.